[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"osteo-arthritis-shoulders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:osteo-arthritis-shoulders":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,85,120],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100485642","exactech-shoulder-post-market-clinical-follow-up-study-100485642",false,"NCT05603728","Exactech Shoulder Post Market Clinical Follow-up Study","An Open Label, Multi-Center, Retrospective and Prospective Evaluation of Shoulder Arthroplasty Clinical and Radiographic Outcomes","Inclusion Criteria:\n\n* Patient is indicated for shoulder arthroplasty (or has previously undergone shoulder arthroplasty)\n* Patient is skeletelly mature\n* Patient is expected to survive at least 2 years beyond surgery\n* Patient is willing to participate by complying with pre- and postoperative visit requirements\n* Patient is willing and able to read and sign a study informed consent form\n\nExclusion Criteria:\n\n* Osteomyelitis of the proximal humerus or scapula; if a systemic infection or a secondary remote infection is suspected or confirmed, implantation should be delayed until infection is resolved\n* Inadequate or malformed bone that precludes adequate support or fixation of the prosthesis\n* Medial humeral bone loss resulting in compromised humeral stem fixation\n* Proximal humeral bone loss extending distal to the surgical neck where there is compromised humeral stem fixation\n* Neuromuscular disorders that do not allow control of the joint\n* Significant injury to the brachial plexus\n* Non-functional deltoid muscles\n* Patient's age, weight, or activity level would cause the surgeon to expect early failure of the system\n* The patient is unwilling or unable to comply with the post-operative care instructions\n* Alcohol, drug, or other subtance abuse\n* Any disease state that could adversaly affect the function or longevity of the implant\n* Patient is pregnant\n* Patient is a prisoner\n* Patient is contraindicated for the surgery\n* Revision cases in which a stemmed humeral component was used (Stemless Shoulder System)\n* Metal allergy or sensitivity to the implants materials (Stemless Shoulder System)\n* Acute fracture of the proximal humerus and displacement of the tuberosities, displaced three or four part fractures of the proximal humerus (hemi-arthroplasty), or acture fracture of the proximal humerus with failure of the glenohumeral joint (total anatomic shoulder arthroplasty) (Stemless Shoulder System)\n* Acute fracture of the proximal humerus in combination with degenerative diseases of the glenohumeral joint and a grossly deficient, irreparable rotator cuff resulting in superior migration of the humeral head (reverse total shoulder arthroplasty) (Stemless Shoulder System)","ALL","21 Years",{"count":19,"type":20},20000,"ESTIMATED","OBSERVATIONAL","The objective of this study is to collect and evaluate long-term clinical and radiographic outcomes data in order to better understand the safety and performance of the shoulder arthroplasty over time. This study will follow subjects long-term for a minimum of 10-years, without an early-term restriction on the amount of time they will be followed.",[24,25,26,27,28,29,30,31,32],"Osteo Arthritis Shoulders","Osteonecrosis","Rotator Cuff Tears","Rotator Cuff Tear Arthropathy","Ankylosing Spondylitis","Post-traumatic Osteoarthritis","Rheumatoid Arthritis","Fracture","Infections","RECRUITING","2025-12-09",{"date":36,"type":37},"2025-12-15","ACTUAL",{"date":39,"type":37},"2007-07-19",{"date":41,"type":20},"2031-12-31",{"name":43,"class":44},"Exactech","INDUSTRY",38,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":58,"conditions":59,"keywords":66,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":84},"100493094","perfusion-mri-targeted-joint-embolization-for-chronic-musculoskeletal-pain-of-the-shoulder-hip-and-knee-100493094","NCT05700682","Perfusion MRI-targeted Joint Embolization for Chronic Musculoskeletal Pain of the Shoulder, Hip and Knee","Perfusion MRI-targeted Joint Embolization to Diagnose and Treat Neovascularity Associated With Chronic Musculoskeletal Pain of the Shoulder, Hip and Knee: A Prospective Cohort Study","MRI","Inclusion Criteria (Both Arms):\n\n1. Participants must be Veterans who receive care in the VA system.\n2. Participants must have a history of chronic pain of the shoulder, hip or knee for at least 1 year.\n3. Participants must have mild to moderate degenerative changes of the painful joint as depicted on prior imaging (X-ray, CT or MRI).\n4. Participants must have undergone at least one failed primary treatment for their chronic pain (e.g. physical therapy, NSAIDs, steroid injection).\n5. Participants must have an MRI of their painful joint (shoulder, hip or knee) ordered by a clinical provider.\n\nInclusion Criteria (Therapeutic Arm):\n\n1. Participants must have enrolled in the Diagnostic Arm of the study and must have undergone perfusion MR imaging of their painful joint.\n2. Participants must have evidence of peri-articular hypervascularity on their perfusion MR exams. This will be determined by the study PIs.\n\nExclusion Criteria (Diagnostic Arm):\n\n1. Acute injury in the last 12 weeks.\n2. Age under 25.\n3. Severe degenerative changes of painful joint (shoulder, hip or knee).\n4. History of arthroplasty or metallic implant within the painful joint.\n5. Severe gadolinium contrast allergy.\n6. Severe renal disease or ongoing dialysis.\n7. History of malignancy with life expectancy of less than one year, or malignancy with known bone metastasis.\n8. Current pregnancy.\n9. Formal diagnosis of cognitive impairment.\n\nExclusion Criteria (Therapeutic Arm):\n\n1. Severe iodinated contrast allergy.\n2. Severe coronary or peripheral arterial disease.\n3. Coagulopathy.\n4. Uncontrolled type 2 diabetes or diabetic neuropathy.\n5. History of seizures or other severe complication from conscious sedation.\n6. Prior upper or lower extremity arterial bypass.\n7. Ongoing participation in another interventional (therapeutic) trial for chronic joint pain.\n8. Lack of peri-articular hypervascularity on initial perfusion MRI.\n9. All exclusion criteria for the Diagnostic Arm.","25 Years","80 Years",{"count":57,"type":20},120,"In this work the investigators will study the relationship between chronic musculoskeletal pain and abnormal blood flow (neovascularity) around the shoulder, hip and knee. Veterans with as history of chronic shoulder, hip or knee pain and mild\u002Fmoderate joint degenerative changes will be potential study subjects. Blood flow around joints will be evaluated using perfusion magnetic resonance imaging (MRI). Participants with demonstrably abnormal blood flow around their painful joint will be eligible for enrollment in a pilot study of joint embolization to treat their pain. Participants who choose to not undergo treatment will be re-assessed with MRI after one year to characterize the natural history of joint neovascularity and its relationship to pain.",[60,61,24,62,63,64,65],"Osteoarthritis, Knee","Osteoarthritis, Hip","Synovitis of Knee","Synovitis\u002FTenosynovitis - Hip","Synovitis","Pain, Chronic",[67,68,69,70,71,72,73],"joint","embolization","neovascularity","pain","knee","hip","shoulder","2025-08-04",{"date":76,"type":37},"2025-08-07",{"date":78,"type":37},"2023-07-15",{"date":80,"type":20},"2026-08-01",{"name":82,"class":83},"Palo Alto Veterans Institute for Research","OTHER",1,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":16,"minAge":93,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":97,"phases":98,"briefSummary":100,"conditions":101,"keywords":106,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":119},"100380788","adipose-derived-biocellular-regenerative-therapy-for-osteoarthritis-100380788","NCT04238143","Adipose-Derived Biocellular Regenerative Therapy for Osteoarthritis","Adipose-Derived Biocellular Regenerative Therapy in Treatment of Osteoarthritis (OA) and Associated Connective Tissue Degeneration and Pain","GARM-MSK-ALD","Inclusion Criteria:\n\n* Documented osteoarthritic inflammatory and\u002For degenerative changes in the joint or connective tissues of the knee, hip, shoulder, Achilles tendon, Sacroiliac Joint, wrist\u002Fhand, foot\u002Fankle, or Plantar Fasciitis (PR);\n* No systemic disorders which, in opinion of principal investigator, would disqualify from safely being able to undergo the determined procedures;\n* Have the ability to understand and accept all items in Informed Consent Document;\n* Have adequate perivascular and extracellular matrix donor tissues available;\n* Mature enough to tolerate determined procedures and follow up instructions and complete post-treatment tracking responsibilities\n\nExclusion Criteria:\n\n* Systemic or psychological impairment which would preclude patient tolerance and understanding nature and extent of procedures and follow up tracking;\n* Known active cancer, chemotherapy, or radiation therapy;\n* Pregnancy;\n* Active infections which would increase risk of patient to undergo treatment;\n* High dose steroid users, or recipients of corticosteroids with a six month period before treatment date;\n* Medication or Opiate addition, or in active treatment for drug rehabilitation;\n* History of documented severe traumatic brain injuries;\n* In the opinion of the principal investigator\u002Fprovider, the patient's condition or medical issues which would not allow the individual to fully accomplish or complete the study requirements","18 Years","90 Years",{"count":96,"type":20},100,"INTERVENTIONAL",[99],"NA","Use of Biocellular and cellular approaches to treatment of Osteoarthritis (OA), musculoskeletal aging processes, pain, and degenerative changes are to be studied with minimally invasive protocols, and non-pharmaceutical means to relieve OA and its associated issues. Traditional surgical interventions have not yielded convincing long-term outcomes, including total joint replacement surgeries and medical management of the supportive structures.\n\nThis study is to use a person's own stem\u002Fstromal Cells (autologous) plus HD-PRP (important healing growth factors and signal molecules) in such cases of OA for long-term minimally invasive treatments. Baseline (existing) findings are documented, and thence tracked as to progress deemed to be result of the intervention.",[102,103,24,104,61,105],"Osteoarthritis","Osteo Arthritis Knee","Osteoarthritis of Multiple Joints","Osteoarthritis - Ankle\u002FFoot",[107,108,109,30],"Arthritis","Degenerative","Joint Disease","2024-09-30",{"date":112,"type":37},"2024-10-01",{"date":114,"type":37},"2020-01-10",{"date":116,"type":20},"2027-09-30",{"name":118,"class":44},"Healeon Medical Inc",2,{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":93,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":130,"conditions":131,"keywords":132,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":84},"100403169","clinical-study-evaluating-outcomes-of-reverse-shoulder-arthroplasty-with-smr-stemless-100403169","NCT04529798","Clinical Study Evaluating Outcomes of Reverse Shoulder Arthroplasty With SMR Stemless","A Monocentric Clinical Study Evaluating Clinical and Patient-reported Outcomes of Reverse Shoulder Arthroplasty With SMR Stemless","SSPR","Inclusion Criteria:\n\n* rotator-cuff arthropathy, osteoarthritis\n* approving written informed consent\n\nExclusion Criteria:\n\n* Female patients who are pregnant, nursing, or planning a pregnancy.\n* All adult patients with any of the SMR Stemless contraindication for use for the reverse configuration as reported in the current local Instruction for use.\n* not consenting in participating in this study",{"count":129,"type":20},60,"The objectives of this study are the assessment of the clinical, radiographical and patient-reported outcomes of SMR Stemless Reverse Shoulder Arthroplasty (LimaCorporate S.p.A.) used as standard of care over a period of at least 2 years of follow-up and the evaluation of the incidence of any complication.",[27,24],[133],"stemless reverse shoulder arthroplasty","2024-07-30",{"date":136,"type":37},"2024-07-31",{"date":138,"type":37},"2016-11-22",{"date":140,"type":20},"2025-08-30",{"name":142,"class":83},"Arthro Medics AG"]